Xeloda () vs Trodelvy (sacituzumab govitecan-hziy)
Xeloda () vs Trodelvy (sacituzumab govitecan-hziy)
Xeloda (capecitabine) is an oral chemotherapy medication that is metabolized into 5-fluorouracil (5-FU) in the body, commonly used to treat colorectal cancer and breast cancer. Trodelvy (sacituzumab govitecan-hziy), on the other hand, is an intravenous antibody-drug conjugate specifically targeting the Trop-2 receptor, which is used for the treatment of metastatic triple-negative breast cancer and has shown promise in other types of cancer as well. The choice between Xeloda and Trodelvy would depend on the specific type and stage of cancer, previous treatments, and the patient's overall health, with Trodelvy being an option for patients with triple-negative breast cancer who have received two prior therapies, at least one of them for metastatic disease.
Difference between Xeloda and Trodelvy
Metric | Xeloda () | Trodelvy (sacituzumab govitecan-hziy) |
---|---|---|
Generic name | Capecitabine | Sacituzumab govitecan-hziy |
Indications | Metastatic colorectal cancer, metastatic breast cancer | Metastatic triple-negative breast cancer (mTNBC), urothelial cancer |
Mechanism of action | Antimetabolite, thymidine phosphorylase activation | Antibody-drug conjugate, topoisomerase inhibitor |
Brand names | Xeloda | Trodelvy |
Administrative route | Oral | Intravenous |
Side effects | Diarrhea, hand-foot syndrome, nausea, vomiting | Neutropenia, diarrhea, nausea, fatigue, alopecia |
Contraindications | Known hypersensitivity to capecitabine or fluorouracil (5-FU) | Known hypersensitivity to sacituzumab govitecan-hziy or its excipients |
Drug class | Antimetabolite chemotherapy | Antibody-drug conjugate |
Manufacturer | Roche | Gilead Sciences (formerly Immunomedics, Inc.) |
Efficacy
Xeloda (Capecitabine) in Breast Cancer Treatment
Xeloda (capecitabine) is an oral chemotherapy drug that is used in the treatment of breast cancer. It is a prodrug that is enzymatically converted to 5-fluorouracil (5-FU) in the body, where it inhibits DNA synthesis and slows the growth of cancer cells. Xeloda is specifically indicated for the treatment of patients with metastatic breast cancer when standard anthracycline-containing therapy has failed, or for patients who are not candidates for such therapies. Clinical trials have demonstrated the efficacy of Xeloda in improving survival rates and reducing tumor size in patients with advanced breast cancer, especially when used in combination with other chemotherapeutic agents.
Trodelvy (Sacituzumab Govitecan-hziy) in Breast Cancer Treatment
Trodelvy (sacituzumab govitecan-hziy) is a first-in-class antibody-drug conjugate (ADC) specifically designed for the treatment of metastatic triple-negative breast cancer (TNBC), a type of cancer that lacks the three most common types of receptors known to fuel most breast cancer growth—estrogen, progesterone, and the HER-2 gene. Trodelvy works by targeting the Trop-2 receptor, which is expressed in the majority of breast cancers, and delivering the anti-cancer drug govitecan directly to the cancer cells. This targeted approach helps to minimize the impact on healthy cells and allows for the delivery of a potent chemotherapy agent directly to the tumor.
The efficacy of Trodelvy was demonstrated in a pivotal Phase III clinical trial, which showed a significant improvement in overall survival and progression-free survival in patients with metastatic TNBC who had received at least two prior therapies for metastatic disease. The results indicated a meaningful clinical benefit, with a substantial increase in median overall survival compared to standard single-agent chemotherapy. Trodelvy has been granted accelerated approval by the FDA based on these results, with continued approval contingent upon verification and description of clinical benefit in confirmatory trials.
Both Xeloda and Trodelvy represent important advancements in the treatment of breast cancer, offering hope to patients with advanced disease. Xeloda provides an oral chemotherapy option for those who have previously been treated with anthracycline-based therapies, while Trodelvy offers a new targeted treatment for patients with the particularly aggressive and difficult-to-treat triple-negative form of breast cancer. Ongoing research continues to evaluate the full potential of these drugs in various combinations and settings within breast cancer therapy.
Regulatory Agency Approvals
Xeloda
Trodelvy
Access Xeloda or Trodelvy today
If Xeloda or Trodelvy are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us